Posted on May 2, 2008 by cartier@bio
My name is Mark Leahey, and I am the Executive Director of the Medical Device Manufacturers Association (MDMA). MDMA is a national trade association representing innovative, entrepreneurial medical technology companies across the country. Our mission is to ensure that patients have timely access to the latest advancements in medical technology, most of which are developed [...]
Filed under: Congress, Non Profit, SBIR | Tagged: MDMA, medical technology, Phase I grants, SBIR | No Comments »
Posted on April 29, 2008 by cartier@bio
Alzheimer’s Drug Discovery Foundation
A new way to look at funding
The Alzheimer’s Drug Discovery Foundation (ADDF) raises money and awards grants to academic and biotechnology industry scientists who are conducting drug discovery research for Alzheimer’s Disease, related dementias and cognitive aging.
The way research is funded is evolving and by employing a venture capital model, [...]
Filed under: Finding Cures, SBIR, patient groups, venture capital | Tagged: Allon, Alzheimer's disease, Comentis, Estee Lauder, Fillit, SBIR | No Comments »
Posted on April 25, 2008 by cartier@bio
The Cystic Fibrosis Foundation today lauded the U.S. House of Representatives for passing legislation to reauthorize the Small Business Innovation Research (SBIR) program.
In response to testimony from Robert J. Beall, Ph.D., president and CEO of the Foundation, the legislation includes a provision requiring that special attention be given to research for rare diseases, such as [...]
Filed under: Congress, SBIR, patient groups | Tagged: Congress, cystic fibrosis, SBIR | No Comments »
Posted on April 24, 2008 by cartier@bio
Yesterday, the House voted overwhelmingly (368-43), to reauthorize the Small Business Innovation Research (SBIR) program. This bill will allow more biotechnology companies to compete for research funding.
This act will increase access to early-stage funding for treatments and cures for debilitating diseases. Congress has recognized the capital-intensive needs of emerging biotechnology companies, whose development of a [...]
Filed under: Congress, SBIR, patient groups, venture capital | Tagged: Committee, House, SBIR, Science, treatments | No Comments »
Posted on April 7, 2008 by cartier@bio
California Biotech Law Blog posted a summary of recent House hearings on reauthorizing the Small Business Innovation Research Program (SBIR).
In the world of biotechnology, the principle at stake is the United States’s claim to be an innovation engine in the global economy. Our members and their scientists are developing disease treatments and cures at a rapid rate, but because these cutting-edge treatments are so new, it takes 10-15 years before they reach the market. In the meantime, they thrive on traditional venture capital and the government’s version of VC: the SBIR program.
If Congress wants to perpetuate the image – and reality – of the US as the center of innovation, they must adapt the criteria for SBIR grants to match the reality for these budding treatments and burgeoning companies.
Filed under: Congress, Finding Cures, SBIR, venture capital | Tagged: biotech, MS, Parkinson's, SBIR | No Comments »
Posted on April 2, 2008 by cartier@bio
What is State Science & Technology Institute (SSTI)?
It is a national nonprofit organization based outside of Columbus, OH, that is dedicated to leading, supporting, and strengthening public-private efforts to improve regional economies through science, technology and innovation. Part of SSTI’s mission is to serve as a neutral convener for discussion and advancement of key issues [...]
Filed under: Congress, Finding Cures, Non Profit | Tagged: Non Profit, research, SBIR, SSTI | No Comments »
Posted on March 25, 2008 by cartier@bio
The Cystic Fibrosis Foundation is the leading organization in the United States devoted to curing and controlling cystic fibrosis. We spoke with Mary Dwight about her organization and the important work they do.
Can you tell us a bit about CFF’s purpose? The Cystic Fibrosis Foundation is the leader in developing drugs to treat and [...]
Filed under: Congress, Finding Cures, SBIR, patient groups | Tagged: Congress, cystic fibrosis, patient groups, SBIR | 2 Comments »
Posted on March 24, 2008 by cartier@bio
House Small Business Committee Holds Hearing on the Reauthorization of the Small Business Innovation Research Program
Witness List
March 13, 2008
Chairwoman Velazquez’s (NY-12) led a lively hearing on the SBIR program in helping small businesses support promising research. She emphasized the importance of reinstating eligibility of majority venture capital-backed companies and highlighted the remedy offered in the [...]
Filed under: Congress, SBIR | Tagged: BIO, Congress, SBIR, venture capital | No Comments »
Posted on March 7, 2008 by cartier@bio
Getting financing can be difficult. This news article from the Worcester Telegram & Gazette demonstrates the importance of SBIR funding.
“Not all start-up companies have been able to tap into venture capital to fund their businesses. Mr. Prescott of Crescent Innovations has secured federal Small Business Innovation Research funding, grants and money from [...]
Filed under: Finding Cures, SBIR, venture capital | Tagged: angel investors, biotechnology, financing, SBIR, start-up, venture capital | No Comments »
Posted on March 7, 2008 by cartier@bio
Putting the “I” back — that is the “I” in innovation. While we consider SBIR program to be critical to the commercialization of biotechnology for our industry, it is clear that others do not share this view ordiffer on the ways in which this problem should be fixed. For example, Kristie Prinz wrote [...]
Filed under: Finding Cures | Tagged: biotechnology, Congress, Innovation, National Research Council, NIH, SBIR | No Comments »
cartier@bio
nicoleatbio
